This from another board absolutely fascinating.
Next data release end of September? Melanoma data? Includes stage III?
By November...more data on systemic RB? More Poetic data?
Scheduled ends of all current P1’s by end of 1st qtr 2021....per mgt...must mean that all P1 recruiting has finished by now because you report when you have PFS and OS data. Logic dictates recruiting finished by now at whatever N. Whatever they got they are going forward on PFS and OS data if they plan to report the end of P1 trials.
Per my past posts. Mgt needs to cozy up with mgt a friendly life science fund before all this. I believe this has already started by buying up what I assume was a portion of maxim warrant conversions. I did not expect maxim to convert it all....that would be dumb at this point if they think this science moves ahead.
Mgt published a systemic RB application to deal with leukemia and other indications. They would never have done so without patent application in place. Other papers indicate a systemic application might be interfering with IL-17....which, in turn, blocks IL-6....research derived from Dr. Kruger’s PH-10 studies...therefore new tech to the industry. RB via PV-10/ PH-10 becomes its own checkpoint inhibitor to interleukins.
For us shareholders here...I’m seeing new tech to the industry coming out. Solid science by independent organizations. Much of this new research is expanding new approaches to new applications. To me...this is nothing more than bolt on tech when talking to big pharma...nothing more. To advance this new tech requires a co-development deal. Our prior tech requires this also. There are over 15 big pharmas playing in this field. I assume mgt knows this as well.
Cancer...solid and blood..,,why?
Psoriasis
Possible new checkpoint inhibitor of interleukins
Can PVCT tech rise to such a broad range of applications like aspirin?....how the RB molecule works...I say yes.
Lots of new tech about RB is coming out. One study says it fixes 100% fungal nail disease. That was proven...,proven! No question.
In truth, RB is such a unique molecule with specific targeting abilities. And that targeting can be applied to many targets. Results of those studies has various degrees of efficacy. From uveal to a bad toenail. While efficacy in different indications vary....targeting disfunctional cells has a common theme. And that is bad cells are acidic...cancer...psoriasis...ect. We own a drug that targets acidity first and foremost.
But wait...you also get interleukin binding....and that opens up all the new tech. That tech address cytokine storms associated with Covid. But wait...it possible blocks ligand links in HIV of CD4+T and CD8+T...,that’s being studied now.
So what made RB in saline so important as PV-10/PH-10?
RB being ionic initially. Hydrophilic. But in saline hydrophobic. Robbing the NA+ out of the saline. Then doing a dance on the cell wall on acidic cells. Flipping hydrophilic heads with hydrophilic tails and then the reverse in the cell walls...which puts RB into the lysosomes...in treating cancer.
But what about IL’s and cytokines? Charge difference over atoms. This can possibly lock up IL’s, when you lock up IL’s...by defacto... you become a checkpoint inhibitor. Thus RB is a IL checkpoint inhibitor.
